MENUNews Archive
Date: 09/20/2023
Rogel Cancer Center faculty and trainees will lead more than 20 presentations, posters and moderated sessions at ASTRO 2023 held October 1-4, at the San Diego Convention Center, San Diego, CA.
Date: 09/14/2023
An inter-departmental group of researchers at the Rogel Cancer Center received a grant from the National Cancer Institute to further research on radiosensitization, the process of making tumors more vulnerable to radiation treatment.
Date: 09/11/2023
A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a study finds. For patients enrolled in Medicare Part D prescription drug plans, out of pocket costs can vary significantly.
Date: 09/08/2023
Historically, genetic testing for cancer risk has been underutilized, especially in underserved communities. The MiGHT Project aims to help Michigan residents at increased risk of cancer get access to clinical genetic testing.
Date: 09/08/2023
To address cancer health disparities in the Native American community, Rogel’s Community Outreach and Engagement team partnered with the Little Traverse Bay Band of Odawa Indians to conduct two motivational interviewing training sessions for care providers from the Good Health Lodge and Crooked Tree Wellness Clinic in Petoskey. The training teaches staff how to communicate with their patients more effectively to lead to better health outcomes.
Date: 09/08/2023
Early findings of two studies from the University of Michigan Health Rogel Cancer Center shed light on new ways to anticipate recurrence in HPV-positive head and neck cancer sooner. The papers, published in Cancer and Oral Oncology, offer clinical and technological perspectives on how to measure if recurrence is happening earlier than current blood tests allow, and provide a framework for a new, more sensitive blood test that could help in this monitoring.
Date: 09/06/2023
Rogel researchers found English speakers who call a hospital general information line were able to get information on next steps to access cancer care 94% of the time, compared to 38% for Spanish speakers, 28% for Mandarin speakers.
Date: 09/06/2023
A study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.
Date: 08/22/2023
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound, called ONC201, nearly doubled survival for patients with diffuse midline glioma or diffuse intrinsic pontine glioma, compared to previous patients.
Date: 08/15/2023
Using tissue samples and cell models from patients, Joshi Alumkal, M.D., Wicha Family Professor of Oncology and leader of the genitourinary medical oncology section at Rogel, and his team zeroed in on the lysine specific demethylase 1, a protein involved in turning genes off and on in normal and cancer cells that appears particularly important in certain aggressive forms of prostate cancer.